Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Latuda Use Patent Suit Could Wrap Up in December: Sumitomo Dainippon Chief
May 14, 2018
- Towa Wins Top Court Victory over Elplat Patent
May 14, 2018
- Kyorin Holdings Aims to Boost New Drug Sales to Over 50% of Overall Sales by FY2019: Pres.
May 14, 2018
- Sumitomo Dainippon’s Sales Hike 14.3% Buoyed by Latuda
May 14, 2018
- Opdivo Sales Dip 13% despite 1.5-Fold Volume Growth: Ono
May 11, 2018
- Astellas Gets Rights to Urology Drug Rosiptor in Asia-Pacific Region
May 11, 2018
- Ono to Boost Oncology Reps to Prep for Opdivo Label Expansions
May 11, 2018
- YL Biologics Files Enbrel Biosimilar in Japan
May 11, 2018
- MSD Japan Seeks Adjuvant Melanoma Nod for Keytruda
May 11, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Shire Buyout a Must for Takeda’s Leap in Global Arena: Board Chair
May 10, 2018
- Shionogi Earmarks 20 Billion Yen in Strategic R&D Investment
May 10, 2018
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Takeda’s Shire Deal Inspiring for Japan Industry Peers: Mitsubishi Tanabe Chief
May 10, 2018
- Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
- AbbVie’s JAK1 Inhibitor Upadacitinib Hits Primary Endpoints in PIIb/III Study in Japanese RA Patients
May 10, 2018
- Taiho’s Lonsurf Extends OS in PIII in Patients with Metastatic Gastric Cancer
May 10, 2018
- Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Quizartinib Prolongs OS in 2nd-Line AML: Daiichi Sankyo
May 9, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…